Merck & Co called off a Phase III trial of its promising cancer drug Xevinapant after an independent panel concluded it is unlikely to meet its goals
Merck shares drop 10% as pharma giant scraps trial of promising cancer drug
Read Next
- Indian central bank likely selling dollars to support rupee near record low, traders say, ET BFSI
- Comcast cable networks spinoff emphasizes need for change in media
- If you recognize these 8 signs, you’re emotionally exhausted (without even realizing it)
- Bitcoin climbs, reaching a new all-time high above $97,000
- 101 Blockchains Black Friday Sale is Starting Early!
- CMC Markets registers 45% Y/Y increase in operating income in H1 FY25
- If you recognize these 9 subtle behaviors, you have a plastic friend in your life
